HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

indium 111-DOTA-lanreotide

Also Known As:

111In-DOTA-lanreotide

Networked: 8 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- indium 111-DOTA-lanreotide: 8
Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - indium 111-DOTA-lanreotide: 8
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - indium 111-DOTA-lanreotide: 8

Experts

1.	Traub-Weidinger, Tatjana: 3 articles (12/2005 - 08/2003)
2.	Virgolini, Irene: 3 articles (12/2005 - 08/2003)
3.	Dudczak, R: 3 articles (09/2001 - 01/2001)
4.	Kurtaran, A: 3 articles (09/2001 - 01/2001)
5.	Raderer, M: 3 articles (09/2001 - 01/2001)
6.	Traub, T: 3 articles (09/2001 - 01/2001)
7.	Virgolini, I: 3 articles (09/2001 - 01/2001)
8.	Raderer, Markus: 2 articles (12/2005 - 08/2003)
9.	Angelberger, Peter: 2 articles (10/2005 - 08/2003)
10.	Dudczak, Robert: 2 articles (10/2005 - 08/2003)

Related Diseases

1.	Thyroid Neoplasms (Thyroid Cancer) 10/01/2005 - "Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET." 10/01/2005 - "First, we investigated in vitro the binding characteristics of 111In-DOTA-lanreotide (111In-DOTA-LAN) and 111In-DOTA-D: Phe1-Tyr3-octreotide (111In-DOTA-TOC) to cells derived from differentiated thyroid cancer (DTC). "
2.	Neoplasms (Cancer) 09/01/2001 - "111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung." 01/01/2001 - "111In-DOTA-lanreotide (LAN), as opposed to 111ln-DOTA-DPhe1-Tyr3-octreotide (TOCT) in tumor patients. " 11/01/1998 - "The 111In-DOTA-lanreotide radiation absorbed tumor dose was significantly higher (ratio 2.25 +/- 0.60, p < 0.01) when directly compared with 111In-OCT. " 11/01/1998 - "The effective half-lives of 111In-DOTA-lanreotide in the tumors were T(eff1) 4.9 +/- 2.2 and T(eff2) 37.6 +/- 6.6 hr, and the mean residence time tau was 1.8 hr. The highest radiation absorbed doses were calculated for the spleen (0.39 +/- 0.13 mGy/MBq), kidneys (0.34 +/- 0.08 mGy/MBq), urinary bladder (0.21 +/- 0.03 mGy/MBq) and liver (0.16 +/- 0.04 mGy/MBq). " 11/01/1998 - "In all patients, tumor sites were visualized during the initial minutes after injection of 111In-DOTA-lanreotide. "
3.	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 08/01/2003 - "111In-DOTA- dPhe1-Tyr3-octreotide, 111In-DOTA-lanreotide and 67Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative study."
4.	Gastrinoma 12/01/1998 - "Before treatment, dosimetry with 111In-DOTA-lanreotide (150 MBq, 10 nmol) indicated a dose of 5.8 mGy/MBq for the recurrent abdominal gastrinoma, and a mean dose of approximately 1.0 mGy/MBq for liver metastases (i.e., 56 and approximately 10 mGy/MBq for 90Y-DOTA-lanreotide, respectively). " 12/01/1998 - "After four infusions of 90Y-DOTA-lanreotide (each 1 GBq, approximately 30 nmol) over a 6-mo period, the 111In-DOTA-lanreotide scintigraphy of the liver had returned to a nearly normal condition and a remarkably decreased uptake by the recurrent gastrinoma was calculated (approximately 5 mGy/MBq for 90Y-DOTA-lanreotide). "
5.	Neoplasm Metastasis (Metastasis) 12/01/1998 - "Before treatment, dosimetry with 111In-DOTA-lanreotide (150 MBq, 10 nmol) indicated a dose of 5.8 mGy/MBq for the recurrent abdominal gastrinoma, and a mean dose of approximately 1.0 mGy/MBq for liver metastases (i.e., 56 and approximately 10 mGy/MBq for 90Y-DOTA-lanreotide, respectively). "

Related Drugs and Biologics

1.	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)
2.	yttrium 90-DOTA-lanreotide
3.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
4.	Citric Acid (Citrate)
5.	Somatostatin Receptors (Somatostatin Receptor)
6.	Radioisotopes (Radionuclides)
7.	Peptides (Polypeptides)
8.	lanreotide (Somatuline)

Related Therapies and Procedures

1.	Intravenous Administration
2.	Therapeutics